Medically reviewed by Jay N. Yepuri, MD Metabolic dysfunction-associated fatty liver disease (MAFLD) occurs when excess fat builds up in the liver. MAFLD can progress to metabolic ...

Deep-learning (DL) radiopathomics models can help predict the presence of vessels encapsulating tumour clusters (VETC) in ...

This study provides compelling real-world evidence that statin use may significantly reduce the risk of both liver cancer and ...

Predictive Safety Testing Consortium have proposed glutamate dehydrogenase (GLDH) as a more liver-specific biomarker for ...

Predictive Safety Testing Consortium have proposed glutamate dehydrogenase (GLDH) as a more liver-specific biomarker for ...

Damaged human livers can repair themselves. Even livers badly scarred from excessive alcohol use, including alcohol-related ...

While acute hepatitis B infection is often resolved by the immune system, CHB occurs when the body's defences are unable to ...

Drug-induced liver injury (DILI) is a significant concern in clinical practice, arising from medications, herbs, and dietary ...

Research published in JAMA Internal Medicine reveals statins may reduce liver cancer risk by 33% and liver complications by ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

A comprehensive study shows that people with fatty liver disease have almost twice the mortality rate of the general population. They have an increased risk of dying from both liver diseases and ...

For patients with chronic liver disease, statin use is associated with reduced risk for hepatocellular carcinoma and hepatic decompensation.